ArticleAmerican journal of physiology. Renal physiology2018
Urine inositol pentakisphosphate 2-kinase and changes in kidney structure in early diabetic kidney disease in type 1 diabetes.
Helen C Looker, Michael L Merchant, Madhavi J Rane, Robert G Nelson, Paul L Kimmel, Brad H Rovin, Jon B Klein, Michael Mauer, CKD Biomarkers Consortium
Article in American journal of physiology. Renal physiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors at 4 institutions in 1 country.
Helen C LookerChronic Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases , Phoenix, Arizona.
Michael L MerchantDivision of Nephrology and Hypertension, University of Louisville , Louisville, Kentucky.
Madhavi J RaneDepartment of Biochemistry and Molecular Genetics, University of Louisville , Louisville, Kentucky.
Robert G NelsonChronic Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases , Phoenix, Arizona.
Paul L KimmelDivision of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases , Bethesda, Maryland.
Brad H RovinDivision of Nephrology, Ohio State University , Columbus, Ohio.
Jon B KleinDepartment of Medicine, University of Louisville , Louisville, Kentucky.
Michael MauerDivision of Renal Diseases and Hypertension, University of Minnesota , Minneapolis, Minnesota.
CKD Biomarkers Consortium
National Institute of Diabetes and Digestive and Kidney Diseases · USUniversity of Louisville · USThe Ohio State University · USUniversity of Minnesota · US
Funding
Epidemiology, Pathophysiology and Treatment of Diabetic NephropathyZIADK069062 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI NELSON, ROBERT G · 2009 to 2023
$10.1M
Proteomic Approach to CKD Biomarker Discovery and ValidationU01DK085689 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI CORESH, JOSEF · 2009 to 2019
$5.6M
Urinary Biomarkers of Chronic Kidney Disease Pathology and ProgressionU01DK085660 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI BONVENTRE, JOSEPH VINCENT, WAIKAR, SUSHRUT S. · 2009 to 2019
$5.3M
"Validation of Novel CKD Biomarkers in CRIC"U01DK085649 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSU, CHI-YUAN, LIU, KATHLEEN D · 2009 to 2013
$4.4M
The New York CKD Biomarker Discovery ProgramU01DK085688 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BOTTINGER, ERWIN P. · 2009 to 2013
$3.0M
Novel biomarker validation and dosing algorithms for anemia management in ESRDR01DK091584 · NIDDK · UNIVERSITY OF LOUISVILLE · PI BRIER, MICHAEL E, MERCHANT, MICHAEL L · 2011 to 2015
$2.6M
Urinary Biomarkers in Biopsy Defined Early Nephropathy in Types 1 and 2 DiabetesU01DK085651 · NIDDK · UNIVERSITY OF MINNESOTA · PI MAUER, S. MICHAEL · 2009 to 2013
$2.2M
Discovery & Validation of Biomarkers of Kidney PathologyU01DK096927 · NIDDK · OHIO STATE UNIVERSITY · PI ROVIN, BRAD H · 2013 to 2017
$2.0M
Forecasters of futute and progressive CDK in patients with microvascular glomerulU01DK085673 · NIDDK · OHIO STATE UNIVERSITY · PI KLEIN, JON, ROVIN, BRAD H · 2009 to 2013
We examined the association of urine inositol 1,3,4,5,6-pentakisphosphate 2-kinase (IPP2K) with the presence and progression of diabetic kidney disease (DKD) lesions. Urine IPP2K was measured at baseline by quantitative liquid chromatography-mass spectrometry in 215 participants from the Renin-Angiotensin System Study who had type 1 diabetes and were normoalbuminuric and normotensive with normal or increased glomerular filtration rate (GFR). Urine IPP2K was detectable in 166 participants. Participants with IPP2K below the limit of quantification (LOQ) were assigned concentrations of LOQ/√2. All concentrations were then standardized to urine creatinine (Cr) concentration. Kidney morphometric data were available from biopsies at baseline and after 5 yr. Relationships of IPP2K/Cr with morphometric variables were assessed by linear regression after adjustment for age, sex, diabetes duration, hemoglobin A
Indexed as
AdultBiomarkersBiopsyChromatography, High Pressure LiquidChromatography, Reverse-PhaseClinical Trials as TopicDiabetes Mellitus, Type 1Diabetic NephropathiesDisease ProgressionFemaleHumansKidneyMaleMass SpectrometryMulticenter Studies as TopicPhosphotransferases (Alcohol Group Acceptor)Biomarkersinositol 1,3,4,5,6-pentakisphosphate 2-kinasePhosphotransferases (Alcohol Group Acceptor)biomarkerdiabetic kidney diseaseinositol pentakisphosphate 2-kinasekidney morphometry
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Urine inositol pentakisphosphate 2-kinase and changes in kidney structure in early diabetic kidney disease in type 1 diabetes. · full record | OpenQuestion